CAMEO-FONTAN -Dapagliflozin in the Failing Fontan Circulation

Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorMayo Clinic

About this trial

The purpose of this research is to determine whether treatment with the study drug dapagliflozin for 3 months affects peripheral venous pressure at rest and during exercise in adults with failing Fontan circulation.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Signed informed consent prior to any study specific procedures

History of Fontan procedure

Male or female subject

Age ≥ 18

Disqualifiers

Type I diabetes

Any of the following medications: Insulin or Pramlintide, Sandostatin, Akeega (abiraterone acetate), Growth Hormone (Somatogrogon-GHLA), Lithium, Chloroquine, Hydroxychloroquine, Thioctic acid (alpha lipoic acid), Empagliflozin or Canagliflozin

Recent hospitalization (<30 days) or revascularization (<90 days)

Significant valvular heart disease (≥moderate stenosis, >moderate regurgitation)

Trial design

Design model

Parallel

Treatments tested in this trial

  • Dapagliflozin tablet

    Drug

    Patient will take a 10mg tablet of Dapagliflozin once daily for 12 weeks

  • Placebo Tablet

    Drug

    Patient will take 10mg placebo tablet once daily for 12 weeks

Treatment groups

27 Participants
are divided into 2 treatment groups
Group A: DapagliflozinExperimental treatment 1 intervention
Group B: PlaceboPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Peripheral venous pressure (PVP) at rest

Peripheral venous pressure (PVP) at rest will be determined by Stress Echocardiogram. Peripheral venous pressure (PVP) is measured in millimeters of mercury (mmHg).

Time frame
Baseline, 12 Weeks
2

Peripheral venous pressure (PVP) with feet elevated

Peripheral venous pressure (PVP) with feet elevated will be determined by Stress Echocardiogram. Peripheral venous pressure (PVP) is measured in millimeters of mercury (mmHg).

Time frame
Baseline, 12 Weeks
3

Peripheral venous pressure (PVP) at 20W exercise

Peripheral venous pressure (PVP) at 20W exercise will be determined by Stress Echocardiogram. Peripheral venous pressure (PVP) is measured in millimeters of mercury (mmHg).

Time frame
Baseline, 12 Weeks

Secondary outcomes

1

Cardiac output at rest

Cardiac output measures the amount of blood the heart pumps per minute. It is calculated by Cardiac Output= Oxygen Consumption/(Arterial - Venous Oxygen Content Difference). Cardiac output will be measured in liters per minute (L/min).

Time frame
Baseline, 12 Weeks
2

Cardiac output with exercise

Cardiac output measures the amount of blood the heart pumps per minute. It is calculated by Cardiac Output= Oxygen Consumption/(Arterial - Venous Oxygen Content Difference). Cardiac output will be measured in liters per minute (L/min).

Time frame
Baseline, 12 Weeks
3

Peak oxygen consumption (VO2) during exercise

Peak oxygen consumption (VO2) is measured in milliliters of oxygen per minute (mL/min).

Time frame
Baseline, 12 Weeks
4

Change in plasma volume

Plasma volume will be determined by radiolabeled iodinated albumin (131I, 5-25 μCu) indicator dilution technique (BVA-100 Blood Volume Analyzer, Daxor Corp, NY). Plasma volume will be measured in milliliters (mL).

Time frame
Baseline, 12 Weeks

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.